Nurhasan Agung Prabowo — Biomedical Watch V2

Traitements3programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Human umbilical vein endothelial cell (HUVEC) exosomesThe goal of this clinical trial is to learn whether a single intravenous injection of exosomes derived from human Wharton's jelly mesenchymal stem cells (HWJ-MSC), given alone or together with exosomes derived from human umbilical vein endothelial cells (HUVEC), is safe and can help slow the progression of chronic kidney disease (CKD) in adults aged 18 to 65 years with stage 3-4 CKD who are not on dialysis. The main questions it aims to answer are: * Does exosome therapy, added to standard CKD care, help preserve kidney function (estimated glomerular filtration rate, eGFR) and reduce urine albumin (urine albumin-to-creatinine ratio, UACR) over 30 days? * Is a single intravenous exosome injection safe and well tolerated? Researchers compared three groups: standard therapy plus a saline (sham) injection, standard therapy plus HWJ-MSC exosomes, and standard therapy plus HWJ-MSC exosomes combined with HUVEC exosomes, to see whether exosome therapy, alone or in combination, improves kidney function and markers of systemic inflammation, fibrosis, oxidative stress, and endothelial dysfunction. Participants: * Received one intravenous injection on Day 1 and were observed closely for 1-2 hours afterwards * Continued their usual standard CKD treatment * Returned for a follow-up visit at Day 30 for blood and urine tests and a clinical examination	Maladie rénale chronique	Phase 1/2	Thérapie cellulaire	Indonesia	À vérifier
Human Wharton's jelly mesenchymal stem cell (HWJ-MSC) exosomesThe goal of this clinical trial is to learn whether a single intravenous injection of exosomes derived from human Wharton's jelly mesenchymal stem cells (HWJ-MSC), given alone or together with exosomes derived from human umbilical vein endothelial cells (HUVEC), is safe and can help slow the progression of chronic kidney disease (CKD) in adults aged 18 to 65 years with stage 3-4 CKD who are not on dialysis. The main questions it aims to answer are: * Does exosome therapy, added to standard CKD care, help preserve kidney function (estimated glomerular filtration rate, eGFR) and reduce urine albumin (urine albumin-to-creatinine ratio, UACR) over 30 days? * Is a single intravenous exosome injection safe and well tolerated? Researchers compared three groups: standard therapy plus a saline (sham) injection, standard therapy plus HWJ-MSC exosomes, and standard therapy plus HWJ-MSC exosomes combined with HUVEC exosomes, to see whether exosome therapy, alone or in combination, improves kidney function and markers of systemic inflammation, fibrosis, oxidative stress, and endothelial dysfunction. Participants: * Received one intravenous injection on Day 1 and were observed closely for 1-2 hours afterwards * Continued their usual standard CKD treatment * Returned for a follow-up visit at Day 30 for blood and urine tests and a clinical examination	Maladie rénale chronique	Phase 1/2	Thérapie cellulaire	Indonesia	À vérifier
Human Wharton's jelly mesenchymal stem cell (HWJ-MSC) exosomesThe goal of this clinical trial is to learn whether a single intravenous injection of exosomes derived from human Wharton's jelly mesenchymal stem cells (HWJ-MSC), given alone or together with exosomes derived from human umbilical vein endothelial cells (HUVEC), is safe and can help slow the progression of chronic kidney disease (CKD) in adults aged 18 to 65 years with stage 3-4 CKD who are not on dialysis. The main questions it aims to answer are: * Does exosome therapy, added to standard CKD care, help preserve kidney function (estimated glomerular filtration rate, eGFR) and reduce urine albumin (urine albumin-to-creatinine ratio, UACR) over 30 days? * Is a single intravenous exosome injection safe and well tolerated? Researchers compared three groups: standard therapy plus a saline (sham) injection, standard therapy plus HWJ-MSC exosomes, and standard therapy plus HWJ-MSC exosomes combined with HUVEC exosomes, to see whether exosome therapy, alone or in combination, improves kidney function and markers of systemic inflammation, fibrosis, oxidative stress, and endothelial dysfunction. Participants: * Received one intravenous injection on Day 1 and were observed closely for 1-2 hours afterwards * Continued their usual standard CKD treatment * Returned for a follow-up visit at Day 30 for blood and urine tests and a clinical examination	Maladie rénale chronique	Phase 1/2	Thérapie cellulaire	Indonesia	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Human Wharton's jelly mesenchymal stem cell (HWJ-MSC) exosomes	Maladie rénale chronique	Phase 1/2	NCT07922889	Mesenchymal Stem Cell Exosomes Alone or Combined With HUVEC Exosomes in Non-Dialysis Chronic Kidney Disease	COMPLETED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.